Fatigue with tirzepatide is a commonly reported concern, though clinical trial data does not list it as a top adverse event
Besides this, it is a major component of hormone replacement therapy in anti-aging clinics
Effect of Interleukin-4 on Vascular Endothelial Growth Factor Production in Rheumatoid Synovial Fibroblasts
For these reasons we believe that the number of past commenters would be a fair estimate of the number of reviewers of this rule
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
